Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

[1]  S. Vincent Rajkumar,et al.  Outcomes of primary refractory multiple myeloma and the impact of novel therapies , 2015, American journal of hematology/oncology.

[2]  S. Trudel,et al.  Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents , 2015, Bone Marrow Transplantation.

[3]  M. Boccadoro,et al.  Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.

[4]  D. Dingli,et al.  Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myeloma , 2012, Cancer.

[5]  Hermann Brenner,et al.  Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. , 2011, The oncologist.

[6]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[7]  P. Moreau,et al.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Horsman,et al.  Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. , 2009, Blood.

[9]  B. Barlogie,et al.  Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. , 2008, Blood.

[10]  D. Dingli,et al.  Impact of early relapse after auto-SCT for multiple myeloma , 2008, Bone Marrow Transplantation.

[11]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[12]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[13]  M. Baccarani,et al.  Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Trudel,et al.  Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Therneau,et al.  Clinical course of patients with relapsed multiple myeloma. , 2004, Mayo Clinic proceedings.

[16]  J. Crowley,et al.  Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[18]  P. Ravaud,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. , 1998, Blood.

[19]  R A Kyle,et al.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2014, Leukemia.

[20]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[21]  P. Sonneveld,et al.  Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials , 2007, Leukemia.

[22]  C. Porta,et al.  Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. , 2003, European journal of cancer.

[23]  B. Barlogie,et al.  The growth fraction of human myeloma cells. , 1981, Blood.